C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/62 (2006.01) A61K 39/385 (2006.01) A61K 39/39 (2006.01) A61K 39/395 (2006.01) C07K 14/705 (2006.01) C12N 5/10 (2006.01) C12N 15/13 (2006.01)
Patent
CA 2207246
The invention relates to a novel antigen that is capable of stimulating the T-cell lymphocyte surface receptor CD40. The adjuvant is a ligand adapted for this purpose. The invention also relates to a novel vaccine incorporating the aforementioned adjuvant and also ideally an antigen that is either a T-cell dependent antigen or a T-cell independent antigen.
Adjuvantix Limited
Fetherstonhaugh & Co.
The University Of Sheffield
LandOfFree
Vaccine development does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine development, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine development will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1719116